logo

For the Inventor, By the Inventor

New York, NY, United States of America

Wyeth


USPTO Granted Patents = 1,309

% Expired Patents = 68.4



Trademarks = 140

Forward Citations = 13,028

Loading Chart...
Loading Chart...

1,563 inventors (with patents filed for the assignee):

goldMedal Gary Paul Stack (61 out of 92 patents)

silverMedal Syed Muzafar Shah (41 out of 94 patents)

bronzeMedal Derek Cecil Cole (34 out of 42 patents)

4.  Eugene John Trybulski (32 out of 32 patents)

5.  Michael G Kelly (31 out of 72 patents)

6.  Hassan Mahmoud Elokdah (31 out of 47 patents)

7.  Andrew Fensome (30 out of 56 patents)

8.  Mark Edward Ruppen (29 out of 59 patents)

9.  Michael Sotirios Malamas (29 out of 76 patents)

10.  Jay Edward Wrobel (26 out of 96 patents)

11.  Puwen Zhang (26 out of 51 patents)

12.  Ronald Charles Bernotas (26 out of 28 patents)

13.  Amedeo A Failli (26 out of 79 patents)

14.  Tianmin Zhu (25 out of 30 patents)

15.  Annaliesa Sybil Anderson (24 out of 59 patents)


Core Competencies:
Pneumococcal Polysaccharide
Antineoplastic Combinations
Designer Osteogenic Proteins
Protein Production
Sustained Release
Immunotherapy Regimes
Mutant Toxins
Nutritional Supplements
Recombinant Protein
Cell Culture
Joint Health
Liquid Formulations

1,309 patents:

1. 12303592 - Formulations for parenteral delivery of compounds and uses thereof (2025-05-20),
2. 12226470 - Pneumococcal dosing regimen (2025-02-18),
3. 12054762 - Methods of protein production using anti-senescence compounds (2024-08-06),
4. 11969474 - Multivalent pneumococcal polysaccharide-protein conjugate composition (2024-04-30),
5. 11535652 - Compositions relating to a mutant clostridium difficile toxin and methods thereof (2022-12-27),
6. 11376315 - Method for controllingpolysaccharide molecular weight using carbon dioxide (2022-07-05),
7. RE48863 - Compositions relating to a mutanttoxin and methods thereof (2021-12-27),
8. RE48862 - Compositions relating to a mutanttoxin and methods thereof (2021-12-27),
9. 11191830 - Process for preparing pneumococcal polysaccharide-protein conjugates (2021-12-07),
10. 11179369 - Sustained release pharmaceutical compositions (2021-11-23),
11. 11167020 - Pneumococcal dosing regimen (2021-11-09),
12. 11103497 - Treatment of imatinib resistant leukemia (2021-08-31),
13. 11077180 - Non-lipidated variants ofORF2086 antigens (2021-08-03),
14. 11008373 - Designer osteogenic proteins (2021-05-18),
15. 10780160 - Process for preparing pneumococcal polysaccharide-protein conjugates (2020-09-22),
Wyeth, headquartered in New York, NY, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative pharmaceutical compositions. The company specializes in a diverse range of core technology topics, including pneumococcal polysaccharide formulations, antineoplastic combinations, and designer osteogenic proteins. Wyeth is also engaged in advanced research on immunotherapy regimes, mutant toxins, and nutritional supplements, contributing significantly to the healthcare landscape with its commitment to improving patient outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Wyeth
1,309 Patents

#12 in New York, NY

#22 in New York

#391 in US

#765 in the World

New York, NY (US)
New York, NY, United States of America

Wyeth

Forward Citations = 13,028

1,563 inventors:

goldMedal Gary Paul Stack (61 out of 92 patents)

silverMedal Syed Muzafar Shah (41 out of 94 patents)

bronzeMedal Derek Cecil Cole (34 out of 42 patents)

4.  Eugene John Trybulski (32 out of 32 patents)

5.  Michael G Kelly (31 out of 72 patents)

Please report any incorrect information to [email protected]
Loading…